CAMP4 Therapeutics Corp. (CAMP)
4.02
+0.11
(+2.81%)
USD |
NASDAQ |
Sep 30, 12:41
CAMP4 Therapeutics Enterprise Value : 118.28M for Sept. 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 29, 2026 | 118.28M |
| September 28, 2026 | 115.16M |
| September 25, 2026 | 118.80M |
| September 24, 2026 | 114.64M |
| September 23, 2026 | 108.41M |
| September 22, 2026 | 130.74M |
| September 21, 2026 | 131.78M |
| September 18, 2026 | 135.41M |
| September 17, 2026 | 124.51M |
| September 16, 2026 | 115.68M |
| September 15, 2026 | 132.82M |
| September 14, 2026 | 135.93M |
| September 11, 2026 | 135.93M |
| September 10, 2026 | 140.61M |
| September 09, 2026 | 140.09M |
| September 08, 2026 | 143.72M |
| September 04, 2026 | 144.24M |
| September 03, 2026 | 148.40M |
| September 02, 2026 | 112.57M |
| September 01, 2026 | 112.05M |
| August 31, 2026 | 120.87M |
| August 28, 2026 | 130.74M |
| August 27, 2026 | 130.22M |
| August 26, 2026 | 133.34M |
| August 25, 2026 | 146.32M |
| Date | Value |
|---|---|
| August 24, 2026 | 139.57M |
| August 21, 2026 | 147.88M |
| August 20, 2026 | 146.84M |
| August 19, 2026 | 156.70M |
| August 18, 2026 | 169.69M |
| August 17, 2026 | 174.88M |
| August 14, 2026 | 197.73M |
| August 13, 2026 | 148.92M |
| August 12, 2026 | 150.47M |
| August 11, 2026 | 131.78M |
| August 10, 2026 | 134.38M |
| August 07, 2026 | 135.41M |
| August 06, 2026 | 148.92M |
| August 05, 2026 | 123.47M |
| August 04, 2026 | 131.26M |
| August 03, 2026 | 133.86M |
| July 31, 2026 | 94.39M |
| July 30, 2026 | 95.43M |
| July 29, 2026 | 85.05M |
| July 28, 2026 | 92.83M |
| July 27, 2026 | 92.83M |
| July 24, 2026 | 79.33M |
| July 23, 2026 | 71.54M |
| July 22, 2026 | 76.74M |
| July 21, 2026 | 80.89M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| MannKind Corp. | 1.360B |
| Ocugen, Inc. | 357.49M |
| ACADIA Pharmaceuticals, Inc. | 2.598B |
| Alnylam Pharmaceuticals, Inc. | 33.66B |
| Anika Therapeutics, Inc. | 253.76M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -33.53M |
| Revenue (Quarterly) | 1.779M |
| Total Expenses (Quarterly) | 35.31M |
| EPS Diluted (Quarterly) | -0.5788 |
| Gross Profit Margin (Quarterly) | 71.89% |
| Profit Margin (Quarterly) | -1.88K% |
| Earnings Yield | -55.35% |
| Normalized Earnings Yield | -36.33 |